Literature DB >> 6360774

Comparison of cimetidine and tripotassium dicitrato bismuthate in healing and relapse of duodenal ulcers.

D R Shreeve, H J Klass, P E Jones.   

Abstract

A comparison between cimetidine and tripotassium dicitrato bismuthate liquid (TDB) in the treatment of endoscopically diagnosed duodenal ulcer by single-blind randomized trial in 48 patients has shown 18 (75%) out of 24 patients receiving TDB and 13 (54%) out of 24 patients receiving cimetidine healed after 4 weeks' therapy. Symptomatic improvement within 1 month was seen in 19 patients on TDB and 18 patients on cimetidine, but did not only occur in patients whose ulcers healed. On follow-up, endoscopically proven relapse occurred within 1 year in 47% of patients whose ulcers had healed during treatment with TDB in comparison with 60% of those healing on cimetidine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6360774     DOI: 10.1159/000198970

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  7 in total

Review 1.  How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.

Authors:  David Y Graham; Sun-Young Lee
Journal:  Gastroenterol Clin North Am       Date:  2015-06-19       Impact factor: 3.806

Review 2.  Gastric cytoprotection. What does it really mean for the prescriber?

Authors:  M Guslandi
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

3.  Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine.

Authors:  P Sikiric; I Rotkvic; S Mise; M Petek; R Rucman; S Seiwerth; V Zjacic-Rotkvic; M Duvnjak; V Jagic; E Suchanek
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

Review 4.  Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials.

Authors:  G Dobrilla; P Vallaperta; S Amplatz
Journal:  Gut       Date:  1988-02       Impact factor: 23.059

Review 5.  Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.

Authors:  A J Wagstaff; P Benfield; J P Monk
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 6.  Long term treatment of duodenal ulcer. A review of management options.

Authors:  G Bianchi Porro; F Parente
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

7.  Twice daily tripotassium dicitrato bismuthate in the treatment of duodenal ulceration.

Authors:  D Hollanders
Journal:  Postgrad Med J       Date:  1986-01       Impact factor: 2.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.